-
-
-
-
-
-
-
EMA validates Pfizer and Valneva's Lyme disease vaccine application
-
-
-
-
-
-
-
Biomea Fusion doses first patient in obesity combo drug study
-
-
-
-
-
-
-
NeOnc Phase 2a brain cancer trial shows 48.9% survival vs. 20% benchmark
-
-
-
-
-
-
-
Definium's LSD-based pill meets Phase 3 goals in anxiety disorder trial
-
-
-
-
-
-
-
Eikon picks dose for phase 2/3 melanoma trial of EIK1001
-
-
-
-
-
-
-
Vertex stock jumps as rival cystic fibrosis drug fails trial
-
-
-
-
-
-
-
Elicio starts Phase 1 pancreatic cancer study of ELI-002 7P
-
76,669 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.

